A Single-center, Open Study Evaluating Efficacy and Safety of XLCART001(CD-19) Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The trial is a single arm, single-center, non-randomized clinical trial which is designed to evaluate the efficacy and safety of XLCART001 in treatment of relapsed/refractory/high-risk B-cell malignancy subjects
100 项与 XLCART001 相关的专利(医药)